摘要
目的:检测miR-34b和miR-155在膀胱尿路上皮癌中的表达,分析其在不同临床病理特征中的表达差别。方法:选取2014年1月至2016年1月我院收治的79例膀胱尿路上皮癌患者为观察组,选取距肿物边缘>3 cm的正常膀胱黏膜组织52例作为对照组,应用实时荧光定量PCR法检测两组中miR-34b和miR-155的表达情况。结果:两组中miR-34b和miR-155的表达差别有统计学意义,观察组中miR-34b和miR-155的表达在不同病变级别、是否浸润、脉管癌栓、淋巴结转移及TNM分期的表达中差别有统计学意义。观察组中miR-34b的表达与增殖指数间呈负相关性,miR-155的表达与增殖指数间呈正相关性。生存分析显示二者的表达与生存时间有关。结论:膀胱尿路上皮癌组织中miR-34b低表达、miR-155高表达,对病变的形成和进展有重要的促进作用。二者对肿瘤的作用可能与对细胞增殖的促进作用有关。术后检测miR-34b和miR-155的表达对判断预后可能有一定价值。
Objective:To detect the expression of miR-34 b and miR-155 in bladder urothelial carcinoma,analyze the difference of miR-34 b and miR-155 expression in different clinicopathological features.Methods:79 patients with bladder urothelial carcinoma were selected as the observation group from January 2014 to January 2016.52 patients with normal bladder mucosa tissues(from the edge of the tumor>3 cm)were selected as the control group.Expression of miR-34 b and miR-155 were detected in the two groups by real-time fluorescence quantitative PCR.Results:The expression of miR-34 b and miR-155 was statistically significant in two groups.The expression of miR-34 b and miR-155 was statistically significant in different pathological grades,infiltration depth,vascular tumor thrombus,lymph node metastasis and TNM staging in observation group.The expression of miR-34 b was negatively correlated with the proliferation index,while the expression of miR-155 was positively correlated with the proliferation index.Expression of miR-34 b and miR-155 were related to survival time by survival analysis.Conclusion:The lower expression of miR-34 b and the higher expression of miR-155 play an important role in bladder urothelial carcinoma.miR-34 b and miR-155 may be related to cell proliferation.Detection of miR-34 b and miR-155 expression may have certain value in judging prognosis.
作者
邱实
何龙
陈鹏
李健
郭时英
杨宏伟
Qiu Shi;He Long;Chen Peng;Li Jian;Guo Shiying;Yang Hongwei(Department of Urology,Northern Theater Command General Hospital,Liaoning Shenyang 110016,China)
出处
《现代肿瘤医学》
CAS
2020年第11期1899-1902,共4页
Journal of Modern Oncology
基金
辽宁省科学技术计划项目(编号:2013225220)。